

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 5/10, A61K 35/76, 48/00</b>		A1	(11) International Publication Number: <b>WO 97/12049</b>
			(43) International Publication Date: 3 April 1997 (03.04.97)
(21) International Application Number: PCT/GB96/02405		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 September 1996 (30.09.96)			
(30) Priority Data: 9519776.0 28 September 1995 (28.09.95) GB			
(71) Applicant (for all designated States except US): MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): RUSSELL, Stephen, James [GB/GB]; 10 Courtyards, Little Shelford, Cambridge CB2 5ER (GB). FIELDING, Adele, Kay [GB/GB]; Annex Flat, The Hall, Six Mile Bottom, Cambridge CB8 0UF (GB). CASIMIR, Colin, Maurice [GB/GB]; Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG (GB).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents: KIDDLE, Simon, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).			

(54) Title: MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS

(57) Abstract

Materials and methods for transferring nucleic acid encoding a polypeptide for treating a disease or disorder into populations of quiescent cells such as haematopoietic stem cells (HSCs), using retroviral packaging cell lines and retroviral particles expressing and displaying a growth factor such as stem cell factor (SCF) on the cell surface or as a fusion with a viral envelope protein. The present invention also relates to compositions comprising the retroviral packaging cell lines and retroviral particles, and their use in methods of medical treatment, *in vivo* and *ex vivo*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Materials and Methods Relating to the Transfer of Nucleic  
Acid into Quiescent Cells

Field of the Invention

5

The present invention relates to materials and methods for transferring nucleic acid encoding a polypeptide for treating a disease or disorder into populations of quiescent cells such as haematopoietic stem cells (HSCs),  
10 using retroviral packaging cell lines and retroviral particles expressing and displaying a growth factor such as stem cell factor (SCF) on the cell surface or as a fusion with a viral envelope protein. The present invention also relates compositions comprising the retroviral packaging  
15 cell lines and retroviral particles, and their use in methods of medical treatment, *in vivo* and *ex vivo*.

Background to the Invention

20 The development of somatic gene therapy as a treatment for single gene inherited diseases and some acquired conditions, such as certain types of cancer, represents one of the most important technical advances in medicine. Blood related disorders such as the X-linked  
25 immunodeficiencies, or chronic granulomatous disease (CGD), are amongst the most favourable candidates as model systems for the evolution of this technology. The general feasibility of gene therapy for disorders of this type has been amply demonstrated by the results obtained in the  
30 treatment adenosine deaminase dependent severe combined immunodeficiency (ADA-SCID) using peripheral blood T-cells.

However, many problems stand in the way of the realisation of the promise of these techniques. For example, in the  
35 experiments described above, the T-cells including the genes required by the patients are not immortal, requiring the therapy to be repeated at regular intervals. Further;

attempts to effect a permanent correction, for example by gene transfer into pluripotent haematopoietic stem cells (PHSC), have thus far been unsuccessful.

5 There are a number reasons for this. Firstly, PHSC are very rare in the bone marrow cell population, and so although work has been done on bone marrow cell culture, it is very difficult to draw conclusions from this work regarding PHSCs. Further, in humans there is a dearth of  
10 markers to identify PHSC and, at present, the most reliable marker of immature human bone marrow cells is the CD34 antigen, which marks about 1-2% of total marrow cells. However, probably only about 0.1% of these CD34+ cells are true PHSC. In addition, there are no wholly reliable  
15 assays for human PHSC, unlike murine systems, where the rescue of lethally irradiated individuals can be used to test for PHSC.

Recently, a method to enrich for PHSC has been described by  
20 Beradi et al (Science, 267, 104-108, (1995)) which exploits the quiescence of PHSCs as a basis for their functional isolation. In this method, bone marrow cells were incubated for 7 days in the presence of the cytokines stem cell factor (SCF) and IL-3, to stimulate division in all of  
25 the progenitor cells, but not in true PHSC. The cytotoxic agent, 5-fluorouracil (5-FU), was then added to these cultures, resulting in the death of all dividing cells in the culture. However, quiescent cells, including PHSC which average only 1 in  $10^5$  of the original cells, were  
30 spared in this process. Accordingly, the authors reported obtaining an enriched population of cells having the characteristics of true PHSC.

However, the authors of this paper were unable to find any  
35 combination of cytokines that was able to stimulate these cells to divide, other than incubation in long term marrow culture (LTC), which also leads to their differentiation.

Thus, although, this method produces highly enriched populations of PHSC, it is their quiescence, the very property exploited for their isolation by Beradi et al, that still represents the most significant hurdle limiting  
5 current gene therapy protocols. This is because most highly developed vector systems presently used for gene transduction are based on murine retroviruses and these viruses (and the vectors derived from them) are unable to stably integrate their genome into non-dividing cells,  
10 rendering PHSCs refractory to retroviral gene transfer.

Previously, we presented an abstract at the European Working Group for Gene Therapy in November 1994 disclosing that a retroviral cell line containing a viral vector  
15 incorporating nucleic acid encoding GCD and expressing stem cell factor on its surface was able to achieve improved rates of transduction in a bone marrow cell culture. However, as mentioned above this cell culture contains a very low proportion of PHSC, and this treatment would not  
20 be expected to stimulate the PHSC to divide or to allow the stable integration of the nucleic acid encoding GCD into the PHSC genome. An important fact underlying this expectation is that in Beradi et al, stem cell factor was one of the cytokines used to stimulate selectively division  
25 in the most of the cells in marrow cell culture (but not the PHSC), allowing them to be killed to leave the enriched population of stem cells.

#### Summary of the Invention

30

The present invention is based on the unexpected finding that it is possible to get haematopoietic stem cells to cycle transiently during the period of exposure to vectors incorporating nucleic acid encoding a desired protein or  
35 polypeptide by exposing them to bound growth factors such as stem cell factor. This observation means that contrary to prior expectations, a population of quiescent cells such

as PHSC can be used as targets for vectors incorporating nucleic acid encoding a desired protein or polypeptide, provided that the cells are additionally exposed to a surface bound growth factor, e.g. stem cell factor  
5 expressed by a retroviral packaging cell line so that it is bound on the cell surface or expressed as a fusion with an envelope protein of retrovirus so that the growth factor is displayed on the surface of the retrovirus.

10 Without wishing to be bound by any particular theory, we believe that the exposure of the quiescent cells to the membrane or surface bound growth factor induces them to start dividing, so that the nucleic acid, e.g. packaged in retroviral particles produced by a retroviral packaging  
15 cell line, can infect the cells and become incorporated into their genomes which become accessible during cellular division when the nuclear membrane dissolves. This method has the advantage that it can be adapted for the treatment of a wide variety of disorders, by incorporating nucleic  
20 acid encoding an appropriate protein or polypeptide into the vector. A further advantage of the method is that by stimulating the quiescent cells to differentiate at the time of gene transfer, preferential amplification of the transduced cells relative to the non-transduced cells can  
25 be achieved.

Accordingly, in a first aspect, the present invention provides a retroviral packaging cell line transformed with a viral vector comprising nucleic acid encoding a  
30 polypeptide for treating a disease or disorder, the retroviral packaging cell line being capable of expressing nucleic acid encoding a growth factor so that the growth factor is (i) displayed on the cell surface or (ii) expressed as a fusion with a viral envelope protein so that  
35 the growth factor is displayed on the surface of viral particles,

wherein the cell line packages the nucleic acid encoding

the polypeptide in viral particles produced by the retroviral packaging cell line, the cell line being for use in a method of medical treatment of a disease or disorder that responds to the polypeptide.

5

In this aspect, the retroviral packaging cell line includes nucleic acid encoding viral envelope protein so that the cell line can produce viral particles and package the nucleic acid encoding the polypeptide for treating the disease or disorder in them.

10

In this application, "quiescent" refers to cells that are unlikely to enter mitosis within the next 24 hours in the absence of appropriate growth stimulus. Preferably, the population of quiescent cells are enriched in haematopoietic stem cells, for instance by employing the isolation method of Beradi et al (supra) using bone marrow cells. Other quiescent cell types suitable for use in the invention include resting T-lymphocytes, B-lymphocytes and monocytes, stem cells of non-haematopoietic tissues such as liver and muscle, epithelial stem cells in skin, gut, bladder and airways, vascular endothelial cells, quiescent neoplastic cells and germ cells such as sperm progenitors.

15

20

In a further aspect, the present invention provides retroviral particles displaying surface bound growth factor as a fusion with an envelope protein, the particles being produced by the retroviral packaging cell line as set out above.

30

In one embodiment, the surface bound growth factor is provided by engineering the retroviral packaging cell line to express growth factor on its surface by transfecting the cell line with nucleic acid encoding the growth factor.

35

In an alternative embodiment, a retroviral vector expressing surface bound growth factor (e.g. SCF) could be

prepared by constructing a packaging cell line engineered to produce a chimeric retroviral envelope protein fused to all or part of the growth factor. The growth factor can be used to replace the natural binding domain of the envelope protein, or can be fused directly to the C- or N- terminus of a retroviral envelope protein. Such chimeric envelopes have been described for use in retroviral targeting (7-9). In this embodiment, the retroviral packaging cell line may also display the growth factor-envelope protein fusion on the surface of the retroviral packaging cell line. The chimeric envelope could be expressed as the sole viral envelope protein in an attempt to target the retrovirus to stem cells, as well as to transduce a growth signal, or in concert with the "wild type" envelope protein, to induce growth in growth factor responsive target cells, without targeting to a specific cell type. The former strategy is more applicable to an *in vivo* situation, the latter to an *in vitro* transduction process. An example of this is the expression of the growth factor as a fusion with viral envelope SU protein of murine leukemia virus (MLV).

In some instances, expressing the growth factor as a fusion with a viral envelope protein, may lead to the nucleic acid encoding the polypeptide not being incorporated into the genome of the target quiescent cells. This can be overcome by introducing a cleavable linker between the viral envelope protein and the growth factor so that the growth factor can be cleaved from the viral particle by addition of a cleaving agent, typically once the quiescent cells start dividing. An example of such a system is the use of a chimeric envelope protein in which viral envelope protein is linked to a factor  $X_a$  linker which is in turn linked to the growth factor. In this system, factor  $X_a$  protease can be used to cleave the growth factor from the surface of the viral particles, so that the particles can transfer the nucleic acid encoding the polypeptide to the target cells where it can be incorporated into their genomes.



Preferably, the surface bound growth factor is FLT3-ligand, or stem cell factor, also known as mast cell growth factor, kit ligand factor or Steel factor. Nucleic acid sequences encoding stem cell factors are described in WO92/00376, eg  
5 the Δ28 MGF stem cell factor.

Preferably, the vector is a retroviral vector such as MFG or the pBabe vector series. Alternatively, present invention could employ a lentiviral vector producer cell  
10 line. In the viral display aspect of the invention, as it is known that the envelope glycoproteins of lentiviral vectors can be substituted by the envelope proteins of C-type retroviruses, the chimeric envelope glycoproteins described below could be used with lentiviral vectors such  
15 as those based on HIV, CAEV or Visna. Further vectors suitable for use in the methods described herein can be readily identified by the skilled person.

Typically, the desired protein or polypeptide will be one  
20 that a patient is unable to synthesise in his or her body or does not synthesise in the usual amount. An example of this is the use of gene therapy to treat adenosine deaminase dependent severe combined immunodeficiency (ADA-SCID). However, the concepts described herein are  
25 applicable to situations in which the nucleic acid encodes a protein or polypeptide that binds a substance that is overexpressed in a patient's body, e.g. causing some harmful physiological effect, or a protein or polypeptide that can bind to a polypeptide that is produced in a  
30 patient's body in an inactive form to activate it or in an active form to inactivate it. Preferably, the use of the present invention in these applications has the advantage that the therapy provided by transfecting the stem cells is long lasting or permanent, thereby helping to avoid the  
35 need for frequently repeated treatment.

Diseases that might be treated using the methods and

materials described herein include all forms of chronic granulomatous disease (CGD), all forms of severe combined immunodeficiency (SCID), hyper gamma globulinaemia syndrome (hyper IgM), Wiskott-Aldrich Disease (WAS), thallassaemia, sickle-cell anaemia, other anaemias due to deficiencies of red blood cell proteins, neutrophil defects due to failure to synthesise granule components, e.g. myeloperoxidase deficiency, haemophilia and other clotting disorders such as complement deficiencies, lysosomal storage disorders, such as Gaucher's disease, Hurler's disease, and mucopolysaccharidosis, leukocyte adhesion deficiency (LAD), bare lymphocyte syndrome, cancer and AIDS.

Other applications of the invention include the genetic modification of haematopoietic stem cells to repopulate the immune system with genetically modified T-lymphocytes that resist HIV, the genetic modification of haematopoietic stem cells to repopulate bone marrow with haematopoietic progenitors that resist the myelosuppressive effects of cytotoxic chemotherapy, and the genetic modification of T-lymphocytes with chimeric T-cell receptors to target cytotoxic T-cells against tumours or virally infected cells.

In a further aspect, the present invention provides compositions comprising a retroviral packaging cell line or retroviral particles set out above, in combination with a suitable carrier. In this aspect, the present invention provides pharmaceutical compositions suitable for delivering nucleic acid encoding a desired polypeptide to a population of stem cells in vitro, e.g. to prepare engineered stem cells for subsequent implant into a patient. Alternatively, the composition could be used in vivo, to directly deliver the nucleic acid to a patient's own stem cells. In this case, the composition preferably comprises a retroviral vector incorporating the nucleic acid encoding a desired protein or polypeptide and

displaying a growth factor on its surface, e.g. as part of an envelope protein.

In a further aspect, the present invention provides the use of a retroviral cell line or retroviral particles as described above in the preparation of a medicament for treating a disease or disorder that responds to the polypeptide encoded by the nucleic acid packaged in the retroviral particles.

In this aspect, preferably the medicament comprising the retroviral packaging cell line or retroviral particles is administered by implantation into a patient's bone marrow or is administered by infusion into a patient's blood. In order to allow the packaging cells to target the bone marrow when administered by infusion, advantageously, receptors such as integrins can be expressed on the surface of the cells. Alternatively or additionally, the immunogenicity of the packaging cells can be reduced by expressing an immunosuppressive factor such as FAS-ligand on the cell surface which can bind to activated T-cell FAS-receptors, triggering the T-cells to die by apoptosis. FAS-ligand expressing allogeneic cell implants have previously been shown to resist immune mediated rejection.

In a further aspect, the present invention provides a method of transforming a population of quiescent cells with nucleic acid encoding a polypeptide so that the nucleic acid is incorporated into the genome of the cells, the method comprising exposing the cells to a retroviral packaging cell line or retroviral particles as described above, wherein the surface bound growth factor induces the cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder contained in the viral particles can incorporate into the genome of the cells.

In this aspect, preferably the quiescent cells are a population of bone marrow cells enriched in haematopoietic stem cells.

5 In further aspects, the present invention provides a population of cells produced by the above method having the nucleic acid encoding a polypeptide for treating a disease or disorder stably incorporated into their genome, and pharmaceutical compositions comprising these populations of  
10 cells.

In a further aspect, the present invention provides a method for introducing nucleic acid encoding a polypeptide for treating a disease or disorder into the genome of a  
15 population of cells in vivo, the method comprising administering a retroviral packaging cell line or retroviral particles by implantation into a patient's bone marrow or by infusion into a patient's blood.

20 By way of example, the present invention will now be described in more detail with reference to the accompanying figures. The following examples are provided to illustrate the present invention, and should not be interpreted as limiting the scope of the claims.

25

#### Brief Description of the Figures

Figure 1. A) top panels, bone marrow cells following 5 days incubation with 5-FU (right) or without 5-FU (left);  
30 bottom panels, staining of cells as above for SCF receptor at completion of 7 days selection in 5-FU (right) or without 5-FU (left). B) PCR analysis of colonies arising from retrovirally transduced, 5-FU selected, stem cells in semi-solid medium following 4 weeks long term culture. 1-9,  
35 colonies; N, negative control; C, positive control; M, size markers. The arrow indicates the retroviral PCR product.

Figure 2. Tritiated thymidine labelling of 5-FU selected cells. Bone marrow cells were incubated as described earlier for 7 days in 5-FU [A], or not [B], after which tritiated ( $^3\text{H}$ ) Thymidine was added to the medium and the cells incubated for a further 16 hrs. Following this incubation they were pelleted onto glass microscope slides using Cytospin (Shandon Instruments). The slides were dipped in photographic emulsion (Ilford) and allowed to dry before incubation in the dark at  $-70^\circ\text{C}$  for one week. The slides were then developed using standard developer and fixer and counter stained with Wright's stain. Cells undergoing division are labelled by the incorporation of  $^3\text{H}$  thymidine into DNA, which leads to the formation of silver grains in the emulsion. The 5-FU treated cells (panel A) show no labelling indicating quiescence, whereas the untreated cells (panel B) show extensive and intense labelling indicative of active cell division.

Figure 3 shows the restriction map of plasmid pJP2 carrying SCF cDNA.

Figure 4 shows schematically the construction of retroviral packaging cell lines expressing membrane-bound SCF.

Figure 5 shows the proliferative response of TF-1 cells to soluble SCF and the membrane bound growth factor. To start this analysis we titrated soluble SCF to against TF-1 cells to establish the optimum concentration of SCF

Figure 6 shows the results of a proliferation assay on TF-1 cells demonstrating that TF-1 cells have a proliferative response to the AM12 cell line alone due to the production of IL6 by the cell line.

Figure 7 shows the titration of anti-IL6 antibody and its effect on the proliferative response of TF-1 cells incubated with AM12 cells only, demonstrating that it is

possible to test for SCF-mediated transduction of quiescent TF-1 cells co-cultured with retroviral producer cells by blocking the IL6-dependent proliferation using anti-IL6 antibody.

5

Figure 8 shows a diagrammatic representation of the plasmid constructs used in example 4 in the production of retrovirus displaying surface bound growth factor as an N-terminal extension of the viral envelope SU protein.

10

Figure 9 is a Western blot showing the chimeric envelope proteins of SCF and FL displaying viruses.

15

Figure 10 is a Western blot showing specific cleavage at the factor X<sub>a</sub> cleavage site of SCFAX1 that upon treatment of the viral pellets with FX<sub>a</sub> protease.

20

Figure 11 shows the effect of SCF competition on tropism of retroviral vectors displaying SCF.

Figure 12 shows tropism of retroviral vectors displaying cleavable and non-cleavable SCF for Kit positive cells.

25

Figure 13 shows a schematic representation of the transduction of stem cells using retroviral packaging cell lines expressing membrane bound SCF.

### Detailed Description

30

### Materials and Methods

#### Cell culture.

35

Bone marrow cells were harvested and stem cells selected using the 5FU technique transduced with retroviral vectors and incubated in long term bone marrow culture all as described in the original application. TF-1 cells were

maintained in RPMI medium supplemented with 10% fetal calf serum, 2mM glutamine, penicillin and streptomycin. Recombinant human GM-CSF was added to 200pg/ml for routine passage and recombinant human SCF at 25ng/ml was used for short term growth support. Packaging and producer cell lines were cultured under the conditions described below and irradiated (500 rads) prior to use in culture experiments.

#### 10 PCNA staining.

Staining of cells for proliferating cell nuclear antigen (PCNA) was performed on cells spun onto microscope slides using a Cytospin (Shandon Instruments) and fixed in methanol, using a mouse anti-human monoclonal antibody (Dako) directly conjugated to FITC. Cells were incubated for 1 hour at room temperature before the antibody solution was washed away with PBS, the slides air-dried, cover-slipped using Citifluor and the fluorescence viewed under UV light using a Zeiss microscope.

#### Construction of LacZ retroviral producer cells expressing surface SCF.

25 A retroviral producer line established in the packaging line AM12 and containing the retroviral vector genome nlsLacZ (12) was used as a target to introduce the plasmid pJP2 by calcium phosphate transfection as described in the original submission. Cells were selected for the presence of the SCF-encoding plasmid using the linked histidinol resistance marker, as described previously.

#### Proliferation assays.

35 Cells were washed twice in PBS pelleted and resuspended in media without growth factor and incubated overnight. Cytokines and <sup>3</sup>H thymidine (10μCi) were added to the media

and the cells incubated for a further 24 hours. The cells were then harvested using a Titertek cell harvester and the incorporated radioactivity counted using a scintillation counter.

5

#### X-gal staining.

For assessing retroviral gene transfer, TF-1 cells were deposited onto microscope slides using a Cytospin (Shandon Instruments) and fixed in PBS buffer containing 0.5% glutaraldehyde.  $\beta$ -galactosidase activity was detected by staining the cells *in situ* with 0.1% X-gal (5chloro-4bromo-3indolyl- $\beta$ -D-galactopyranoside.) in PBS buffer containing, 0.01% sodium deoxycholate, 0.02% NP40, 2mM  $MgCl_2$ , 5mM potassium ferricyanide and 5mM potassium ferrocyanide for 1-2 hours at 37°C.

15

#### Tritrated thymidine labelling.

For  $^3H$  thymidine labelling TF-1 cells were transduced with retroviral vector as described above in RPMI media to which 10 $\mu$ Ci of  $^3H$  thymidine was added. After overnight labelling, the cells were deposited onto microscope slides and stained for  $\beta$ -galactosidase activity before being washed dried and dipped in photographic emulsion. The emulsion was allowed to air dry overnight and the slides were exposed at -70°C in a light tight box for 3 days. To visualise the  $^3H$  thymidine incorporation the emulsion was developed and fixed using standard X-ray film developer and fixer and cells producing silver grains were assessed by light and dark field light microscopy.

25

30

#### Example 1

Retroviral transduction of quiescent target cells with retroviral producer cells expressing surface growth factor (SCF); the establishment of a model system.

35



To demonstrate the feasibility of using producer cells that express surface growth factor to transduce quiescent cells with retroviral vectors, we have developed a model system using the growth factor-dependent cell line TF-1 (12).  
5 This cell line was developed from an erythroleukaemic patient and probably equates to cell arrested at an early stage of megakaryocyte development. The cells can only be grown in the presence of growth factors, the most usual being IL-3 or GM-CSF to which they respond very  
10 sensitively. They also are capable of dividing in response to SCF though this response is significantly weaker. These cells can easily be rendered quiescent by withdrawal of growth factor support. We used these cells as targets for retroviral transduction, following induction of quiescence.

15 In order to facilitate this analysis, we constructed a retroviral producer line expressing surface SCF (see figure 4). This was done by transfecting the same plasmid we had constructed before containing the hSCF cDNA (plasmid pJP2,  
20 figure 3), into retroviral producer cells transducing a retroviral vector encoding the gene for  $\beta$ -galactosidase (NLSlacZ). This bacterial enzyme can be used in conjunction with synthetic substrates to produce a blue staining reaction when active enzyme is present.  
25 Accordingly, in these experiments, successfully transduced cells will stain blue following retrovirally mediated gene transfer. The resulting producer line was identified as LacJP. Immunofluorescent staining of the LacJP cell line with anti-SCF antibody showed the presence of the surface  
30 bound SCF.

We compared the proliferative response of TF-1 cells to soluble SCF and the membrane bound growth factor. To start this analysis we titrated soluble SCF to against TF-1 cells  
35 to establish the optimum concentration of SCF (figure 5). TF-1 cells were then grown in the presence of soluble recombinant human SCF or in the presence of the lac JP cell

line or the parent packaging cell line (AM12). These initial experiments quickly revealed, however, that the retroviral packaging cell line produced a growth factor that was a potent mitogen for the TF-1 target cells (figure 6). It was previously described in the literature that packaging cells lines were sources of the cytokine IL-6. We hypothesised that mitogen secreted by the retroviral packaging cells might be IL-6. To test this we attempted to block the response to IL-6 in our cultures by the addition of neutralising antibody to the cytokine. Titration of the neutralising antibody (figure 7) demonstrated that it was possible to completely eradicate the IL-6 mediated proliferative response of TF-1 cells when co-cultured with retroviral producer cells. All the subsequent experiments were therefore performed in the presence of inhibitory amounts of anti-IL-6.

We then tested the ability of our modified producer cells to facilitate transduction of quiescent target cells. TF-1 cells in exponential growth were removed from growth factor and incubated overnight to allow them to become quiescent. TF-1 cells were then co-cultured overnight with the retroviral producer cells expressing surface SCF or the parent producer line. Following co-culture, the TF-1 cells were removed collected onto microscope slides and stained for  $\beta$ -galactosidase production. Cells that were co-cultured on the parent producer line showed no evidence for retroviral transduction. In contrast, approximately 3% of cells that were co-cultured with the SCF producer cells were found to be positively staining. These were confirmed as cycling TF-1 cells by doubly-labelling the cells with titrated thymidine ( $^3\text{H}$ ). This radioactive nucleoside becomes incorporated into the DNA of dividing cells and can be detected by autoradiographic deposition of silver grains in a photographic emulsion into which the slides have been dipped. As expected, many of the transduced TF-1 cells also showed the presence of silver grains indicating that

cell division had taken place.

Thus, these experiments show that expression of a surface bound growth factor by retroviral producer cell lines is able to facilitate the retroviral transduction of a quiescent target cell population and therefore enable the retroviral-mediated transfer of genes to cells that would normally be refractory to this technique.

10 Example 2

Retroviral transduction using populations of cells isolated from umbilical cord blood.

15 We carried out a transduction experiment similar to those described above using haematopoietic progenitor cells obtained from human umbilical cord blood. Progenitors were selected from cord blood using the Macs™ (Miltenyi Biotech) system to isolate CD34+ progenitor cells (15). The CD34+ population in cord blood is made up extensively of quiescent cells (13,16). These cells were transduced in vitro as described above by co-culture for 48 hours in the presence of the nlsLacZ producers or the LacJP producers. The cord blood cells were then harvested and pelleted onto microscope slides and stained for  $\beta$ -galactosidase activity as described above. Cells that had been exposed to the nlsLacZ producers had a low proportion of blue-staining cells (<10%), whereas those that had been exposed to the LacJP producers that expresses SCF on its surface had a very high proportion of blue-stained cells (>80%). In addition, blue-staining colonies formed by subsequent growth of these populations of cells in semisolid media were only found in cultures derived from cells that had been co-cultured with the LacJP cell line.

Example 3

5 Retroviral transduction of haematopoietic stem cells using a retroviral packaging cell line expressing surface bound SCF.

(a) Production of the retroviral packaging cell line.

10 The cell line 1MI-ΔSCF was constructed as follows: the parent producer cell line 1MI was derived from the Am12 packaging cell line (1), by calcium phosphate-mediated DNA transfection, using the retroviral vector encoding the p47-phox cDNA we described previously (2), with the exception that the neomycin resistance cassette was removed. The  
15 retroviral backbone is derived from the pBabe series of vectors described by Morgenstern et al (3). High titre producer clones were then selected by "dot blot" analysis of successful transfectants. The 1MI producer line was then transfected as described above using the plasmid pJP2  
20 (figure 3) encoding the membrane-associated form of the human stem cell factor (SCF). Cells expressing SCF were selected using histidinol. Individual clones were grown out and tested for expression of SCF by immunofluorescence with a labelled anti-SCF antibody. The plasmid pJP2 was  
25 constructed by insertion of an 816bp HindIII to BamHI, SCF cDNA fragment into the mammalian cell expression plasmid pREP8 (Invitrogen Corp). The SCF cDNA was excised from the plasmid BSSK: huMGFΔ28, see WO92/00376.

30 (b) Selection and transduction of PHSC.

Bone marrow cells (10mls; approx  $5 \times 10^7$  cells) were aspirated from the iliac crest of normal volunteers under local anaesthesia. The cells were washed twice with sterile PBS,  
35 re-pelleted and layered onto the surface of a discontinuous ficoll gradient. Cells were separated by centrifugation for 20 mins at 2500 rpm. Mononuclear cells were removed

from the interphase and washed with PBS. Cells were then incubated in Iscove's DMEM medium supplemented with 10 % fetal calf serum, 5-fluorouracil (5-FU), stem cell factor (SCF) and IL-3, as described by Beradi et al (Science 267  
5 1995). Following seven days in selection (see Fig 1A), the surviving cells were co-cultured for 48hrs in the presence of the SCF-producer line. Following co-cultivation, they were removed from the producers and used to establish long term cultures (LTC) on heterologous irradiated human  
10 stroma, in McCoy's medium modified for long term culture. After 4 weeks in LTC, cells were plated in semi-solid media containing cytokines (StemGEM™), to allow colonies to develop.

15 (c) Detection of transduced cells.

Transduction was scored by PCR analysis of colonies (Fig 1B). The PCR relied on a nested strategy using two upstream and one downstream primers. An initial round of  
20 35 cycles of amplification using the most upstream primer and the downstream primers was performed. A small aliquot of this reaction was removed and re-amplified in a second reaction using the second upstream primer and the downstream primer. The most upstream primer is  
25 complementary in sequence to a region from the gag gene of the retroviral vector and the other two primers are complementary to different regions from the p47-phox cDNA sequence. The size of the initial product is 454 nucleotides and the nested product 180 nucleotides. This  
30 strategy ensures that the PCR product is specific for the retrovirally encoded p47-phox gene and not the endogenous gene. The products of the PCR amplification were visualised under ultra-violet light (300nm) following separation by standard agarose gel electrophoresis on 2%  
35 gels containing ethidium bromide.

Table 1: PCR Colony Data (Ethidium Bromide Staining)

Experiment	+Colonies/Total SCF	+Colonies/ Total Control	% + SCF	% + Control	Fold increase with SCF
1	5/20	-	25	-	-
2	5/30	0/30	17	0	>5
3*	11/30	1/30	37	3	11
4	19/30	7/20	63	35	2
5	5/30	-	17	-	-
6	4/30	0/30	13	0	>4

\* Expt 2 re-evaluated using Southern Blot hybridisation.

The data set out in table 1 shows that in five separate experiments on marrow cell cultures indicated that approximately 13% and 63% of colonies were positive for the presence of the retroviral genome, showing that the retroviral vector had succeeded in delivering the p47-phox gene to the PHSCs.

In addition, the data presented as experiment 2 was re-evaluated using a different, more sensitive, method (Southern blotting), demonstrating an 11-fold increase in the rate of transduction of the 5FU-selected PHSC following exposure to the retroviral producers that express stem cell factor on their surface. As no positive colonies were obtained from the controls in two experiments (Experiments 2 and 6), the increased rates of transduction can only be expressed as greater than 5 or 4 times better than the control respectively. These values can therefore be considered as the absolute minimum in terms of the benefit of using the SCF-expressing producers; the actual value may be considerably greater.

(iv) PCNA staining.

A nuclear antigen referred to as "proliferating cell nuclear antigen" (PCNA) a component of the DNA replication machinery can be used as a marker of cells in the process or capable of undergoing cell division. As such, staining cells with antibody to this antigen can give information on the cycling status of cells in a chosen population. Staining of PHSC selected by the 5FU technique with a monoclonal antibody to PCNA (PC10), revealed that the majority of the cells (~90%, figure 1a and Table 2) were unlabelled and were therefore quiescent, as expected. These cells were then cultured for 48 hours in the presence of the SCF-expressing producer line or the control parent cell line and stained with the PC10 antibody. Cells that had been exposed to the SCF producers showed a marked increase in the fraction of positively staining cells (~50% and table 2).

Table 2: PCNA staining

Cells	+ cells*		Total + cells	% + cells
5FU cells	8/73	3/42	11/115	9.5
Post SCF	9/17	9/18	18/35	51.4
Post Control	0/10	-	0/10	0

\* Cells were counted from two different random views under microscopical examination. Insufficient control cells were obtained to enable two counts to be made.

#### Example 4

Production of a retrovirus displaying surface bound growth factor as an N-terminal extension of the viral envelope SU protein.

(a) Construction of chimeric envelope expression plasmids.

5 Plasmids were created encoding chimeric envelopes in which stem cell factor (SCF) or Flt3 ligand (FL) is fused to the first codon of the SU envelope glycoprotein as a factor Xa cleavable or non-cleavable N-terminal extension of the 4070A (amphotropic) murine leukaemia virus (MLV).

10 SCF and FL cDNA was PCR amplified and tailed with SfiI and Not I restriction sites. The PCR products were cloned into existing chimeric envelope expression plasmids EA1 and EXA1 (10) after digestion with the restriction enzymes SfiI and Not I. Figure 8 shows a diagrammatic representation of the plasmid constructs. The sequences of all the constructs  
15 was confirmed by dideoxysequencing.

(b) Production of viruses.

20 The chimeric envelopes and control amphotropic (4070A) envelopes were expressed in TelCeB.6 complementing cells, which express MLV gag-pol core particles and a nlsLacZ retroviral vector. Envelope expression plasmids were transfected by calcium phosphate precipitation into the TelCeB.6 cells. Transfected cells were selected with  
25 phleomycin and blasticidin in DMEM supplemented with 10% foetal calf serum (FCS) and grown to confluency. Viral supernatants were harvested from stably transfected cells after overnight incubation in either serum free DMEM or DMEM containing 10% FCS and filtered with a 0.45µm filter  
30 for use in infection or binding experiments. For immunoblotting, viral supernatants were filtered (0.45µm) and then pelleted by ultracentrifugation at 30,000 rpm in a SW40 rotor for one hour at 4°C. The pelleted viral particles were re-suspended in 100µl of phosphate buffered  
35 saline and stored at -20°C.



(c) Target cells.

The murine cell line NIH 3T3 was grown in DMEM supplemented with 10% FCS. The human SCF receptor (Kit) expressing cell  
5 line HMC-1 was grown in Iscove's modified Dulbecco's eagle medium (IMDM) supplemented with 10% FCS and monothioglycerol. The human kit negative cell line K422 was grown in RPMI supplemented with 10% FCS.

10 (d) Immunoblots.

Ten  $\mu$ l of the pelleted viral particles were separated on a 10% polyacrylamide gel under reducing conditions and subsequently transferred to nitrocellulose. The viral SU  
15 proteins were detected using a primary goat anti-envelope antibody. Blots were developed using a secondary anti-goat antibody conjugated to horseradish peroxidase and an enhanced chemiluminescence kit.

20 (e) Infections.

Target cells were plated into six-well plates at approximately  $10^5$  cells per well and incubated overnight at 37°C (adherent cells) or plated into six well plates at  
25 approximately  $10^6$  cells per well one hour before infection (suspension cells). Filtered viral supernatant in serum free medium was added to the target cells and incubated for 4 hours in the presence of 8 $\mu$ g/ml polybrene.

30 The retroviral supernatant was then removed from the target cells, the medium was replaced with the usual medium and the cells were placed at 37°C for a further 48-72 hours. X-gal staining for detection of  $\beta$ -galactosidase activity was carried out as previously described (11). Viral titre  
35 was calculated by counting blue stained colonies microscopically and expressed as enzyme forming units per ml (adherent cells) or percentage blue stained cells

(suspension cells).

(f) Immunoblotting of pelleted virus.

5 The viral pellets of both SCF and FL displaying viruses  
were analysed by immunoblotting and a representative blot  
is shown in figure 9. The presence of chimeric viral  
envelope with a distinct mobility from that of the wild  
type virus is demonstrated. Figure 10 shows that upon  
10 treatment of the viral pellets with 4µg/ml FX<sub>2</sub> protease, the  
FX<sub>2</sub> cleavage signal in the interdomain linker of the  
expressed envelope SCFXA1 is correctly recognised and  
cleaved to yield a SU cleavage product with identical  
mobility to the unmodified 4070A envelope SU.

15

(g) Host range properties of vectors incorporating the  
chimeric envelopes.

20 Viral supernatant harvested from cells transfected with the  
various constructs was used to infect mouse fibroblasts.  
Gene delivery to the 3T3 cells was demonstrated for the  
amphotropic chimeras and was unaffected by protease  
cleavage. Thus viral infectivity mediated by the  
underlying envelope was not blocked by display of these  
25 dimeric ligands.

The infectivity of viruses incorporating the SCFA1 and  
SCFXA1 chimeric envelopes was tested on HMC-1 cells - a  
human Kit expressing cell line. Both vectors were capable  
30 of binding to Kit positive cells but gave very low titres  
compared to the wild type vector. When soluble SCF was  
added as competitor to prevent the vectors from binding to  
Kit, the infectivity was increased, suggesting that the  
reduced ability of these vectors to bind to Kit positive  
35 cells was a consequence of targeted binding to SCF  
receptors (figure 11). These vectors were then treated  
with factor X<sub>2</sub> protease prior to infection. Pre-incubation

with FXa had no effect on the titre of the SCFA1 vector but restored the titre of SCFXA1 to that of the wild-type amphotropic vector (figure 12). This effect of FX<sub>a</sub> cleavage did not occur on the Kit negative cell line K422. This data provides evidence that retroviral vectors displaying SCF are capable of selectively binding to human cells expressing Kit but that infection of Kit positive cells cannot take place until the engineered binding domain has been cleaved. In this respect, this ligand-receptor systems resembles the EGF system developed in our laboratory (11) and is potentially amenable to the two-step targeting strategies developed for EGF.

### Discussion

The above results show that good levels of transduction of PHSC can be achieved using engineered retroviral packaging cells expressing human SCF on their cell surface. Thus, the results above indicate that the cells should be capable of simultaneously delivering both a growth signal and a retroviral vector to the target PHSC. This simultaneous delivery of vector and growth signal should also have the advantage of increasing the effective retroviral titre, owing to the intimate association of producer and target cells.

SCF has been shown to have both soluble and membrane-bound forms. Evidence acquired from the study of mice carrying a small intragenic deletion in the gene encoding the SCF receptor has indicated that the membrane-bound form of the cytokine is essential for normal haematopoiesis. Despite being able to synthesise a soluble SCF retaining full biological activity, these mice are as badly affected as their counterparts who carry a complete deletion of the gene. While not wishing to be bound by any particular theory, we believe that the *in vivo* biological activities of the soluble and membrane-associated forms of the growth

factor are distinct, and that normal haematopoiesis has an absolute requirement for the membrane-bound form of SCF that cannot be substituted by the soluble form. It may also be that the expression of bound SCF on the cell surface changes/reduces the extent to which other growth factors are expressed, and that this has a beneficial effect on transduction levels of the PHSC.

Improved transduction rates using the method may be achieved using the synergistic action of additional cytokines. In this regard, SCF is particularly noted for its property of interacting in this way with other growth factors, which has led to the suggestion that on its own it may not be a mitogen but acts as an anti-apoptotic factor. To assess this, similar experiments to those described above can be performed using additional cytokines added to the media in conjunction with our modified producers. Ideally, we would hope to find conditions favouring self-renewal at the expense of differentiation. This would have the highly desirable consequence of enabling us to expand PHSC numbers in culture. One factor thought possibly to act in this way is MIP1- $\alpha$ 1. There is also evidence that stem cell quiescence may be negatively influenced by TGF- $\beta$ , antagonists of this molecule may therefore be beneficial in stimulating cells into cycle. Of the positively acting cytokines, LIF, the factor that blocks differentiation of mouse embryonal stem cells and IL-11, a recently identified member of the same family of cytokines, are candidates for acting on stem cells, as is flt3 ligand, a molecule with a similar spectrum of activities to SCF.

As regards embodiments of the invention using growth factors displayed on the surface of retroviruses, the results presented above demonstrate that the dimeric ligands SCF and FL can successfully be displayed on retroviruses and that these ligands retain the capability of binding to their receptors. We have demonstrated that,

although infection cannot be mediated through the displayed ligand, if a protease cleavable linker is used to fuse the displayed ligand to the viral envelope, targeted infection can result. The modified viruses described here retain  
5 their capacity to infect cells through the Raml receptor but other results from our laboratory indicate that it is possible to construct a cleavable linker which is capable of blocking infection through the natural viral receptor. In should therefore be possible to target retroviral gene  
10 transfer specifically to PHSC.

The above method describes a protocol which is potentially applicable to any clinical procedure requiring the transfer of genetic information to pluripotent haematopoietic stem  
15 cells (PHSC). As discussed above, this method is applicable for gene therapy of inherited haematopoietic disorders, such as the immunodeficiencies, but it could also be applicable to conditions such as haemophilia, or other conditions requiring the synthesis of a  
20 pharmacologically active compound normally present in the serum. There are also potential applications in the field of cancer therapy, primarily as a way of protecting cells from cytotoxic agents or radioprotecting them, thus giving them a survival advantage over non-treated bone marrow  
25 cells.

References:

The references mentioned in this application are all herein incorporated by reference.

- 5        1.    Markowitz, D., S. Goff, and A. Bank. 1988.  
         Construction and use of a safe and efficient  
         amphotropic packaging cell line. *Virology* 167:400.
- 10       2.    Thrasher, A., M. Chetty, C. Casimir, and A. W. Segal.  
         1992. Restoration of Superoxide Generation to a  
         Chronic Granulomatous Disease-Derived B-Cell Line by  
         Retrovirus Mediated Gene Transfer. *Blood* 80:1125.
- 15       3.    Morgenstern, J. P. and H. Land. 1990. Advanced  
         mammalian gene transfer: high titre retroviral vectors  
         with multiple drug selection markers and a  
         complementary helper-free packaging cell line.  
         *Nucleic Acids Res.* 18:3587.
- 20       4.    Anderson, D. M., D. E. Williams, R. Tushinski, S.  
         Gimpel, J. Eisenman, L. A. Cannizzaro, M. Aaronson, C.  
         M. Croce, K. Huebner, and D. Cosman. 1991. Alternate  
         splicing of mRNAs encoding human mast cell growth  
         factor and localisation of the gene to chromosome  
25       12q22-12q24. *Cell Growth Differ* 2:373.
- 30       5.    Beradi, A. C., A. Wang, J. D. Levine, P. Lopez, and D.  
         T. Scadden. 1995. Functional isolation and  
         characterization of human hematopoietic stem cells.  
         *Science* 267:104.
- 35       6.    Mullis, K., F. Faloona, S. Scharf, R. Saiki, G. Horn,  
         and H. Erlich. 1986. Specific enzymatic amplification  
         of DNA in vitro: the polymerase chain reaction. *Cold  
         Spring Harb Symp Quant Biol* 51: 263.

7. Russell, S.J., R.E. Hawkins, and G. Winter, 1993. Retroviral vectors displaying functional antibody fragments.
- 5 8. Valesia-Wittman, S., A. Drynda, G. Delange, M. Aumailley, J.M. Heard, O. Danos, G. Verdier, and F.L. Cosset. 1994. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. *J. Virol.*, 68:4609.
- 10 9. Kasahara, N., A.M. Dozy and Y.N. Kan. 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. *Science*, 266:1373.
- 15 10. Nilson BHK, Morling FJ, Cosset F-L, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. *Gene Therapy* 1996, 3:280-286.
- 20 11. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. *J Virol* 1994, 68: 8001-8007.
- 25 12. Bagnis, C., Gravis, G., Imbert, A.M., Herrera, D., Allario, T., Galindo, R., Lopez, M., Pavon, C., Sempere, C., and Mannoni, P. (1994). Retroviral transfer of the nlsLacZ gene into human CD34+ cell populations and into TF-1 cells: future prospects in gene therapy. *Hum. Gene Ther.*, 5, 1325-1333.
- 30 13. Broxmeyer, H.E., Lu, L., Cooper, S., Ruggieri, L., Li, Z.H., and Lyman, S.D., (1995). Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. *Exp. Hematol.*, 23, 1121-1129.

14. Einerhand, M.P., Bakx, T.K., and Valerio, D., (1991).  
IL-6 production by retrovirus packaging cells and  
cultured bone marrow cells. Hum. Gene Ther., 2, 301-  
306.
- 5
15. Krause, D.S., Fackler, M.J., Civin, C.I., and May,  
W.S., (1996). CD34: structure biology and clinical  
utility, Blood, 87, 1-13.
- 10
16. Leitner, A., Strobl, H., Fischmeister, G., Kurz, M.,  
Romanakis, K., Haas, O.A., Printz, D., Buchinger, P.,  
Bauer, S., Gadner, H., and Fritsch, G. (1996). Lack  
of DNA synthesis among CD34+ cells in cord blood and  
in cytokine mobilized blood. Br. Haematol 192, 255-  
15 262.



CLAIMS:

1. A retroviral packaging cell line transformed with a viral vector comprising nucleic acid encoding a polypeptide for treating a disease or disorder, the retroviral packaging cell line being capable of expressing nucleic acid encoding a growth factor so that the growth factor is (i) displayed on the cell surface or (ii) expressed as a fusion with a viral envelope protein so that the growth factor is displayed on the surface of viral particles,

wherein the cell line packages the nucleic acid encoding the polypeptide in viral particles produced by the retroviral packaging cell line, the cell line being for use in a method of medical treatment of a disease or disorder that responds to the polypeptide.

2. The retroviral packaging cell line of claim 1 wherein the medical treatment is transfer of the nucleic acid encoding the polypeptide to a population of quiescent cells which are induced to divide by the surface bound growth factor, so that the nucleic acid is incorporated into the genome of the quiescent cells.

3. The retroviral packaging cell line of claim 1 or claim 2 wherein the cells are haematopoietic stem cells.

4. The retroviral packaging cell line of any one of claims 1 to 3 wherein growth factor is stem cell factor or FLT3 ligand.

5. The retroviral packaging cell line of claim 4 wherein growth factor is stem cell factor.

6. The retroviral packaging cell line of any one of the preceding claims further expressing nucleic acid encoding a receptor to target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or

immunosuppressive factor are displayed on the cell surface.

5 7. Retroviral particles displaying a surface bound growth factor as a fusion with an envelope protein, the particles being produced by the retroviral packaging cell line of any one of the preceding claims.

10 8. The retroviral particle of claim 7 wherein the growth factor is SCF or FLT3-ligand.

9. The retroviral particles of claim 7 or claim 8 wherein the growth factor is attached to the N-terminus of a retroviral envelope protein.

15 10. The retroviral particle of any one of claims 7 to 9 wherein envelope protein is viral envelope SU protein.

20 11. The retroviral particle of any one of claims 7 to 10 wherein the growth factor is fused to the envelope protein via a cleavable linker.

12. The retroviral particles of any one of claims 7 to 11 wherein the particle displays multiple growth factors.

25 13. A composition comprising a retroviral packaging cell line or retroviral particles of any one of claims 1 to 12, in combination with a suitable carrier.

30 14. A retroviral packaging cell line expressing nucleic acid encoding a growth factor as a fusion with an envelope glycoprotein so that the growth factor is displayed on the surface of the cell line.

35 15. The retroviral packaging cell line of claim 14 wherein the growth factor is FLT3-ligand.

16. The retroviral packaging cell line of claim 14 or

claim 15 wherein the cell line is a lentiviral packaging cell line.

- 5 17. The use of a retroviral cell line or retroviral particles of any one of claims 1 to 12 in the preparation of a medicament for treating a disease or disorder that responds to the polypeptide encoded by the nucleic acid packaged in the retroviral particles.
- 10 18. The use of claim 17 wherein the medicament comprising the retroviral packaging cell line or retroviral particles is administered by implantation into a patient's bone marrow or by infusion into a patient's blood.
- 15 19. The use of claim 18 wherein the retroviral packaging cell line expresses a receptor to target the cells to the bone marrow and/or an immunosuppressive factor on their surface.
- 20 20. A method of transforming a population of quiescent cells with nucleic acid encoding a polypeptide so that the nucleic acid is incorporated into the genome of the cells, the method comprising exposing the cells to a retroviral packaging cell line or retroviral particles of any one of
- 25 claim 1 to 12, wherein the surface bound growth factor induces the cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder contained in the viral particles can incorporate into the genome of the cells.
- 30 21. The method of claim 20 wherein the quiescent cells are a population of bone marrow cells enriched in haematopoietic stem cells.
- 35 22. A population of cells produced by the method of claim 20 or claim 21 having the nucleic acid encoding a polypeptide for treating a disease or disorder stably

incorporated into their genome.

23. A pharmaceutical composition comprising the cells of claim 22.


5

24. A method for introducing nucleic acid encoding a polypeptide for treating a disease or disorder into the genome of a population of cells *in vivo*, the method comprising administering a retroviral packaging cell line or retroviral particles of any one of claims 1 to 12 by implantation into a patient's bone marrow or by infusion into a patient's blood.

10

1/9

Fig.1.



B






Fig.2.

A



B



BEST AVAILABLE COPY

Fig.3.

3/9




Fig.4.




Fig.5.

4/9





Fig.6.



- A: TF-1 CELLS INCUBATED WITH 25 ng/ml rhSCF  
B: TF-1 CELLS INCUBATED WITH AM12 CELLS EXPRESSING CELL SURFACE SCF (I.E. THE lacJP CELLS)  
C: TF-1 CELLS INCUBATED WITH AM12 CELLS ONLY

SUBSTITUTE SHEET (RULE 26)



Fig.7.





Fig.8.



7/9

Fig.9.





Fig.10.



BEST AVAILABLE COPY

8/9

Fig.11.






Fig.12.



BEST AVAILABLE COPY

9/9



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 96/02405

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/86 C12N5/10 A61K35/76 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 00103 A (WISTAR INST ;UNIV PENNSYLVANIA (US)) 7 January 1993 see the whole document ---	1-24
X	WO 93 25234 A (UNIV CALIFORNIA) 23 December 1993 see the whole document ---	1-24
X	WO 94 27643 A (TARGETED GENETICS CORP ;PAUL RALPH W (US); OVERELL ROBERT (US)) 8 December 1994 see the whole document ---	1-24
X	WO 94 06920 A (MEDICAL RES COUNCIL ;RUSSELL STEPHEN JAMES (GB); HAWKINS ROBERT ED) 31 March 1994 see the whole document ---	1-24
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

Date of the actual completion of the international search

6 February 1997

Date of mailing of the international search report

07.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (- 31-70) 340-3016

Authorized officer

Hillenbrand, G

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 96/ 02405

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 24  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 96/02405

## C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 00294 A (MEDICAL RES COUNCIL ;RUSSELL STEPHEN JAMES (GB); COSSET FRANCOIS L) 4 January 1996 see the whole document ---	1-7, 9-14, 16-24
E	WO 96 33281 A (VIAGENE INC ;SYSTEMIX (US)) 24 October 1996 see the whole document -----	1-7, 9-14, 16-24



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/02405

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9300103	07-01-93	BR-A- 9300910	15-11-94
WO-A-9325234	23-12-93	EP-A- 0650370	03-05-95
		JP-T- 7507689	31-08-95
WO-A-9427643	08-12-94	AU-A- 7097494	20-12-94
WO-A-9406920	31-03-94	AU-A- 4827893	12-04-94
		CA-A- 2145063	31-03-94
		EP-A- 0670905	13-09-95
		JP-T- 8504091	07-05-96
WO-A-9600294	04-01-96	AU-A- 2749595	19-01-96
WO-A-9633281	24-10-96	AU-A- 5557196	07-11-96